Figure 5. The α-PD-L1 treatment reduces the PD-L1⁺ cells in TME.

B6 mice were intraperitoneally inoculated with 5 × 10⁵ MC38-luc cancer cells and treated with VV and/or α-PD-L1 as described. Tumour-bearing mice were killed at day 5 post first treatment and primary tumours were collected and analysed to determine the PD-L1⁺ CD45⁻ cells (a,b), PD-L1⁺ DC (defined as CD45⁺ CD11b⁺CD11c⁺Ly6G⁻PD-L1⁺) (c), PD-L1⁺G-MDSC (defined as CD45⁺CD11c⁻CD11b⁺Ly6G⁺Ly6c^lowPD-L1⁺) (d), PD-L1⁺ M-MDSC (defined as CD45⁺CD11c⁻CD11b⁺Ly6G⁻Ly6c^hiPD-L1⁺) (e), PD-L1⁺ TAM1 (defined as CD45⁺CD11c⁻CD11b⁺Ly6G⁻F4/80⁺CD206⁻PD-L1⁺) (f), PD-L1⁺ TAM2 (defined as CD45⁺CD11c⁻CD11b⁺Ly6G⁻F4/80⁺CD206⁺PD-L1⁺) (g). Of note, the anti-PD-L1 antibody clone 10F.9G2 was used for therapy while clone MHI5 was used for subsequent analysis. Data were analysed using Student's t-test (*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001).